BSE filing, NSE: PANAMAPET. Summary written from the filing by ALFA Finder's alert engine.
Panama Petrochem Ltd: key numbers
- Share price
- ₹450.60
- Market cap
- ₹2,726 Cr
- Revenue (annual)
- ₹3,064 Cr
- Net profit (annual)
- ₹212.5 Cr
- P/E (TTM)
- 5.7×Sector 17.7×
- Promoter holding
- 63.16%+0.00% QoQ
- FII holding
- 11.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Panama Petrochem Ltd
All →Panama Petrochem Board Meeting Date
Panama Petrochem scheduled a board meeting for November 4, 2026, to consider unaudited half-yearly results for September 2026. Trading window stays closed until November 6, 2026.
Panama Petrochem Credit Rating
Panama Petrochem Limited received a positive rating outlook revision from CARE Ratings for its long-term bank facilities, while short-term bank facility ratings were reaffirmed.
Panama Petrochem Other Announcement
Panama Petrochem Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations. This routine disclosure provides details of shareholder stakes for the period ending September 2026.
Panama Petrochem Annual General Meeting
Panama Petrochem Ltd concluded its 44th AGM on August 24, 2026. Shareholders approved all resolutions, including the adoption of financial statements and declaration of dividend.
Panama Petrochem Q1 FY27 Results: Net Profit ₹308.9 Cr, Up 625.1% YoY
Panama Petrochem Ltd reported revenue from operations of ₹1,735 Cr (+150.3% YoY) and net profit of ₹308.9 Cr (+625.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹308.9 Cr · +625.1% YoY
Panama Petrochem Board Meeting Date
Panama Petrochem Ltd scheduled a board meeting for August 12, 2026. The board will consider financial results for the June 30, 2026 quarter.
Other regulatory approval announcements
All →Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.